Novartis Intends to Buy MorphoSys for $3 Billion, Future of Pelabresib in Doubt Novartis Intends to Buy MorphoSys for $3 Billion, Future of Pelabresib in Doubt Novartis Announces Acquisition Deal with MorphoSys In an industry-altering move, Novartis, the renowned pharmaceutical company, has declared its intention to purchase the German biotech firm MorphoSys for a staggering … Read more
NEW YORK Market participants are apparently optimistic that the US Federal Reserve will not raise interest rates further on Wednesday, commented analyst Edward Moya from broker Oanda. After ten increases in a row, bank economists are now also expecting a monetary policy pause due to the cooling economy and the trend towards falling inflation. Another … Read more
(AWP) The Novartis subsidiary Sandoz strengthens its portfolio for the treatment of respiratory diseases. For this purpose, the British Coalesce Product Development was taken over, the generics division announced on Monday. The British company specializes in the development of medical devices and drugs. This expands the existing portfolio of respiratory drugs, the statement continues. No … Read more
The British food and consumer goods manufacturer Unilever wanted to buy its consumer health division from GlaxoSmithKline (GSK) for 50 billion pounds (about 1.5 trillion crowns). It operates as a joint venture in partnership with the American pharmaceutical company Pfizer. GSK announcedthat Unilever submitted a total of three offers last year, but the company rejected … Read more
Frankfurt The success of the Covid-19 vaccine developer Biontech has brought new attention to German biotech companies. However, regardless of the success of Biontech, the industry has again moved more into the focus of venture capitalists, even if financing and production are still more difficult in Germany than in the USA. The cancer specialist is … Read more
Laggard pharmaceuticals could be about to receive a post-pandemic booster shot. The actions of GlaxoSmithKline, Novartis or Sanofi have suffered during the confinements, as routine procedures and treatments have been postponed. But with the economic reopening they should recover. The health sector has had its share of winners for Covid, such as Moderna. But some … Read more
A drug from Novartis does not appear to be effective against Covid. Photo: dpa / Karl-Josef Hildenbrand – — The active ingredient ruxolitinib from Novartis does not work against Covid. In one study, the incidence of severe complications was similar to that of patients who had only received a placebo. – Zurich – Setback for … Read more
If you enter the production facility for cell and gene therapies in Stein, this wall with the LED lights catches your eye. Wall of Hope called them Novartis CEO Vas Narasimhan when the plant opened a little over a year ago. For every batch of Kymriah that leaves Stein, a small lamp is lit. Each … Read more
Novartis has agreed to pay more than $ 642 million to end prosecutions by the American justice system, which accused the Swiss pharmaceutical group, in particular, of having paid large underpayments to doctors, the ministry said on Wednesday. American Justice. • Read also: More than 130 therapies under study according to the pharmaceutical industry • … Read more
You are now leaving the finanzen.at website and will be redirected to the Onvista Bank website. Please note that the course dates given on finanzen.at may differ from those on the Onvista Bank website. Therefore, check all the data carefully before you make the purchase or sale on the Onvista Bank website. Contents of external … Read more